EyePoint Pharmaceuticals, Inc. — Director's Dealing 2022

Feb 11, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: EyePoint Pharmaceuticals, Inc. (EYPT)
CIK: 0001314102
Period of Report: 2022-02-09

Reporting Person: Lurker Nancy (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-02-09	Common Stock	M	17533.00	$0.00	Acquired	124098.00	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-02-09	Restricted Stock Units	$0.00	M	17533.00	Disposed		Common Stock (17533.00)	Direct
2022-02-09	Restricted Stock Units	$0.00	A	60000.00	Acquired		Common Stock (60000.00)	Direct
2022-02-09	Stock Option (Right to Buy)	$10.13	A	240000.00	Acquired	2032-02-09	Common Stock (240000.00)	Direct

Footnotes

F1: Includes 3,019 shares acquired on January 31, 2022 pursuant to EyePoint's 2019 Employee Stock Purchase Plan.

F2: The restricted stock units vest in three ratable annual installments beginning February 9, 2022.

F3: These restricted stock units will vest in three ratable annual installments beginning February 9, 2023.

F4: The option to purchase will vest and become exercisable as follows: 25% at February 9th, 2023 and the remainder ratably, on a monthly basis, over the remaining three years.